Month: October 2026

Motion to Dismiss Defeated in Case Against Kyverna

Scott+Scott Attorneys at Law LLP this week defeated Defendants’ Motion to Dismiss in a securities class action against the biopharmaceutical company Kyverna Therapeutics, Inc. The case alleges that Kyverna’s top executives omitted material information in their IPO prospectus about the development and negative clinical results of cell therapies for autoimmune diseases. When the truth emerged in June 2024, Kyverna’s share price dropped drastically causing significant financial harm to investors.